8-K: ORIC-944 Shows Strong Clinical Activity in Prostate Cancer

ORIC Pharmaceuticals reports updated Phase 1b data for ORIC-944, demonstrating strong clinical activity and a favorable safety profile in metastatic castration-resistant prostate cancer patients.

Summary

• ORIC Pharmaceuticals provided an update on ORIC-944 dose exploration data from its Phase 1b combination trial.
• The trial involves patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with an ARPI (e.g., abiraterone, enzalutamide, apalutamide, or darolutamide).
• The update includes data from 20 patients, with 17 previously disclosed in May 2025.
• ORIC-944 in combination with apalutamide or darolutamide demonstrated strong clinical activity, with 55% (11/20) achieving an unconfirmed PSA50 response and 40% (8/20) a confirmed PSA50 response.
• A PSA90 response was observed in 20% (4/20) of patients, both unconfirmed and confirmed.
• Rapid and deep ctDNA reductions were observed, with 76% of patients demonstrating >50% ctDNA reduction.
• The ctDNA clearance rate (59% detected to not detected) was superior to standard of care therapies in comparable mCRPC populations (e.g., enzalutamide, docetaxel/cabazitaxel).
• The combination therapy was generally well-tolerated, with the vast majority of adverse events being Grade 1 or 2, and no Grade 4 or 5 treatment-emergent adverse events (TEAEs) attributed to ORIC-944.
• Dose exploration with apalutamide and darolutamide is complete, and dose optimization is ongoing, with preliminary data expected in Q1 2026.

Sentiment

Score: 9

Explanation: The filing presents highly positive clinical data for ORIC-944, demonstrating strong efficacy in PSA and ctDNA responses, a favorable safety profile, and superiority in ctDNA clearance compared to existing treatments. This significantly de-risks the asset and suggests strong potential for future development and commercialization.

Positives

• Strong clinical activity observed with ORIC-944 in combination with apalutamide or darolutamide in post-abiraterone mCRPC patients.
• High PSA response rates: 55% unconfirmed PSA50, 40% confirmed PSA50, and 20% confirmed PSA90.
• Impressive molecular response with rapid and deep ctDNA reductions, with 76% of patients showing >50% ctDNA reduction.
• Superior ctDNA clearance rate (59% detected to not detected) compared to standard of care therapies in comparable mCRPC populations.
• Generally well-tolerated safety profile, with the vast majority of adverse events being Grade 1 or 2, and no Grade 4 or 5 TEAEs attributed to ORIC-944.
• Safety profile is compatible with long-term dosing and compares favorably to competitor PRC2 inhibitor (mevrometostat) + enzalutamide and enzalutamide monotherapy.
• PSA responses were observed across all dose levels and were comparable between apalutamide and darolutamide combinations.
• ctDNA responses were observed across a breadth of genotypes, including tumors with AR mutations, AR amplified, AR wildtype, and tumor suppressor/oncogene mutations.

Risks

• The timing of the initiation, progress, and results of preclinical studies and clinical trials.
• Risks associated with developing and commercializing safe and effective drugs and operating as an early clinical stage company.
• Negative impacts of health emergencies, economic instability, or international conflicts on operations, including clinical trials.
• The potential for current or future clinical trials to differ from preclinical, initial, interim, preliminary, or expected results.
• Ability to advance product candidates into, and successfully complete, clinical trials.
• The timing or likelihood of regulatory filings and approvals.
• Changes in plans to develop and commercialize product candidates.
• Estimates of patient numbers for targeted diseases and clinical trial enrollment.
• Commercializing product candidates, if approved.
• Ability to successfully manufacture and supply product candidates for clinical trials and commercial use.
• Potential benefits and costs of strategic arrangements, licensing, and/or collaborations.
• Risk of termination of license or collaboration agreements.
• Estimates regarding expenses, future revenue, capital requirements, and needs for financing, and ability to obtain capital.
• Sufficiency of existing cash and investments to fund future operating expenses and capital expenditure requirements.
• Ability to retain key personnel and to identify, hire, and retain additional qualified professionals.
• Implementation of business model and strategic plans.
• Scope of intellectual property protection.
• Ability to contract with third-party CROs, suppliers, and manufacturers and their performance.
• Pricing, coverage, and reimbursement of product candidates, if approved.
• Developments relating to competitors and the industry, including competing product candidates and therapies.
• Regulatory developments in the United States and foreign countries.
• General economic and market conditions.

Future Outlook

Dose optimization for ORIC-944 in combination with AR inhibitors is ongoing, with preliminary data expected in the first quarter of 2026. The company continues to develop ORIC-944, aiming for best-in-class properties and further clinical outcomes from combination studies.

Management Comments

• ORIC-944 in combination with AR inhibitors has been generally well tolerated with the vast majority of adverse events Grade 1 or 2 and consistent with PRC2 and AR inhibition.
• ORIC-944 plus AR inhibitor safety profile compatible with long-term dosing, with the vast majority of AEs Gr 1 or 2, and no Gr 4/5 events.
• ORIC-944 plus apalutamide or darolutamide demonstrated a higher ctDNA clearance rate than observed in precedent trials with standard of care therapies.

Industry Context

The announcement positions ORIC-944 as a potentially superior treatment option for metastatic castration-resistant prostate cancer (mCRPC) patients who have previously received ARPIs. The data suggests ORIC-944's combination therapy offers strong clinical activity and a favorable safety profile compared to existing standard of care therapies and a competitor PRC2 inhibitor, indicating a potential competitive advantage in a significant oncology market.

Comparison to Industry Standards

• ORIC-944 + Apalutamide or Darolutamide demonstrated PSA50 (40% confirmed) and PSA90 (20% confirmed) responses.
• The safety profile of ORIC-944 + AR inhibitors (e.g., Diarrhea 60%/5% Gr3, Fatigue 45%/0% Gr3) compares favorably to Mevrometostat + Enzalutamide (Diarrhea 78%/17% Gr3, Fatigue 56%/5% Gr3) and Enzalutamide monotherapy (Fatigue 43%/3% Gr3, Diarrhea 18%/0% Gr3).
• ORIC-944 + AR inhibitor showed a ctDNA clearance rate of 59% (Detected to Not Detected on Tx) in patients previously treated with abiraterone.
• This ctDNA clearance rate is superior to those observed in precedent trials with standard of care therapies, such as Enzalutamide in IMbassador250 and Docetaxel or Cabazitaxel in FIRSTANA/PROSELICA.

Stakeholder Impact

• Shareholders: Positive impact due to promising clinical trial results, which could increase the company's valuation and future revenue potential.
• Patients: Potential for a new, more effective, and well-tolerated treatment option for metastatic castration-resistant prostate cancer.
• Investment Professionals: Provides strong data for evaluating ORIC Pharmaceuticals' pipeline and investment potential.
• Regulatory Authorities: The positive data will be crucial for future regulatory filings and approvals.

Next Steps

• Ongoing dose optimization for ORIC-944 in combination with AR inhibitors.
• Expectation of preliminary data from the dose optimization phase in Q1 2026.
• Continued clinical development of ORIC-944.

Key Dates

Recommendation

The updated Phase 1b data for ORIC-944 is highly encouraging, showing strong clinical activity with significant PSA and ctDNA responses, coupled with a favorable safety profile that compares positively against current standard-of-care and competitor treatments. The superior ctDNA clearance rate is a particularly strong indicator of potential long-term efficacy. This data substantially de-risks the ORIC-944 program and suggests a high probability of success in later-stage trials, positioning ORIC Pharmaceuticals for significant growth in the mCRPC market. The ongoing dose optimization and expected Q1 2026 data provide clear near-term catalysts.

Keywords

ORIC-944, Prostate Cancer, mCRPC, Clinical Trial, Phase 1b, AR Inhibitor, Apalutamide, Darolutamide, PSA Response, ctDNA, Oncology, Biotechnology, Drug Development, SEC Filing